

## CLAIM AMENDMENTS

Claims 1-274 (canceled)

275. (currently amended) ~~A~~ An isolated multimeric composition comprising a binding matrix and more than one monomeric unit, wherein each monomeric unit comprises two elements covalently attached to one another, wherein a first element is a protein, wherein said protein is a ligand to a cell surface receptor, wherein a second element is a single-stranded polynucleotide and wherein each monomeric unit is separately attached to a ~~said~~ binding matrix through said second element via hydrogen bonding between said single-stranded polynucleotide of said monomeric unit and said binding matrix, wherein said binding matrix is a polynucleotide, comprising sequences complementary to said single-stranded polynucleotide.

Claims 276-289 (canceled)

289. (withdrawn) A process for delivering the multimeric complex of claim 275 to a subject comprising introducing the complex to one or more cells ex vivo and administering said cells to said subject.

290. (withdrawn) A process for delivering the multimeric complex of claim 275 to a subject comprising administering said complex to said subject.

Claims 291-295 (canceled)

296. (previously presented) The composition according to claim 275, wherein said ligand to a cell surface receptor is a hormone.

297. (previously presented) The composition according to claim 296, wherein said hormone is insulin.

298. (withdrawn) The composition according to claim 275, wherein said ligand to a cell surface receptor is a growth factor.

299. (withdrawn) The composition according to claim 298, wherein said growth factor is erythropoietin.

300. (withdrawn) The composition according to claim 275, wherein said ligand to a cell surface receptor is a cytokine.

301. (withdrawn) The composition according to claim 300, wherein said cytokine is a lymphokine.